OncoMatch/Clinical Trials/NCT03114462
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
Is NCT03114462 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies non-drug interventions for malignant neoplasms of respiratory and intrathoracic organs.
To find the highest tolerable dose of stereotactic hypofractionated radioablation (HYDRA) radiation that can be given to patients with laryngeal cancer. The safety of this radiation will also be studied.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Disease stage
Required: Stage T1N1, T2N0, T2N1, T3N0, T3N1, T4AN0, T4AN1 (AJCC)
Stage T1N1/T2-4aN0-1 disease, as defined by American Joint Committee on Cancer (AJCC) criteria
Performance status
ECOG (ZUBROD) 0–2
Prior therapy
Cannot have received: surgery
Cannot have received: induction chemotherapy
Cannot have received: radiation therapy
Lab requirements
Liver function
No hepatic insufficiency resulting in clinical jaundice and/or coagulation defects
Cardiac function
No unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months; no transmural myocardial infarction within the last 6 months
Severe, active co-morbidity, defined as follows: a. Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months. b. Transmural myocardial infarction within the last 6 months. ... e. Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify